Trump Scores A Drug Pricing Win For Pharma In The UK
The Trump administration leveraged tariffs to convince the UK National Health Service to increase prices for new medicines by 25%.
Scrip - December 1, 2025

German Medtechs Encouraged By Government Strategy Kick-Off And Support For EU MDR Change
Pragmatic solutions are called for to ensure that German medical device manufacturing and innovation remain competitive in global terms, federal health minister Nina Warken told a hearing of medtech industry leaders.
Medtech Insight - December 1, 2025

Distributors In Spotlight As OIG Highlights US Medicare’s Major Overspend On CGMs
US Medicare payments for CGMs and supplies in the year to June 2023 exceeded suppliers’ acquisition costs by $377m, says new OIG report
Medtech Insight - December 1, 2025

EIB and Angelini Ventures Link Up To Back European Startups
The €150m agreement is music to the ears of biotechs battling to find cash.
Scrip - December 1, 2025

European Commission Dismisses Calls For Pause On Waste Water Directive
The European Commission says it will soon publish an updated study on the impact of the Urban Waste Water Treatment Directive on the pharmaceutical and cosmetics industry and that it would support member states in avoiding “unintended consequences.”
Generics Bulletin - December 1, 2025

Stock Watch: How Hedge Funds Profit From Big Pharma Stocks
Pair trade strategies – using the stocks of two companies competing against each other with similar products – can be applied to pharmaceutical companies. Better still, where a winner and loser are correctly anticipated, a directional bias can increase profits.
Scrip - December 1, 2025

Opella Keeps French Commitments with €40m Investment
Opella is honoring its commitment to maintaining production volumes, investment levels, and jobs at its French plants by spending €40m to upgrade two sites in the country.
HBW Insight - December 1, 2025

Lupin Eyes Global Ophthalmology Growth
Entering 2026, Lupin is positioning itself for growth, with a keen focus on the expanding ophthalmology market.
In Vivo - December 1, 2025

Four Firms Fire Starting Pistol On European Denosumab Competition
Four companies have confirmed launches of denosumab biosimilars in Europe, setting the stage for a competitive market for Prolia and Xgeva biosimilars.
Generics Bulletin - December 1, 2025

Zydus Builds On US Specialty Portfolio With A 505(b)(2) Deal
Zydus inks a new 505(b)(2) oncology deal, taking over the commercialization of RK Pharma’s undisclosed sterile injectable in the US.
Generics Bulletin - December 1, 2025

Commercial Lessons From The Cell And Gene Therapy Frontlines
Executives leading the commercialization of cell and gene therapies are informing how the industry approaches everything from manufacturing strategy to physician education.
In Vivo - December 1, 2025

Bias-Proofing RWD And AI For Faster, Fairer Trials?
The verdict from the front lines of drug development is unmistakable: RWD and AI won’t transform trials through hype alone – they deliver only when welded to airtight data practices, transparent models and accountable operations.
In Vivo - December 1, 2025

Philips Debuts Spectral CT With AI At RSNA 2025
Verida optimizes the entire imaging chain with AI, lowering system noise, elevating image quality and accelerating clinical workflow and marks a transformative milestone in CT, Philips claims.
Medtech Insight - December 1, 2025

What’s Next? Five Things To Look Out For In December 2025
Generics Bulletin previews the most noteworthy and anticipated events for December 2025.
Generics Bulletin - December 1, 2025

Ceribell’s Neonatal US Clearance Sets Up 2026 Growth Amid China Pressures
Ceribell’s algorithm analyzes EEG data collected through a headcap equipped with sensors can identify subclinical events unnoticed without continuous monitoring.
Medtech Insight - December 1, 2025

Quick Listen: Scrip’s Five Must-Know Things
This week: 2027 medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J’s Alzheimer’s asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas’s Padcev's first big win in bladder cancer study.
Scrip - December 1, 2025